Programmed death protein 1(PD-1)and programmed death protein ligand-1(PD-L1)play pivotal roles in maintaining immune homeostasis and a crucial link in tumour immune evasion.PD-1/PD-L1 inhibitors have achieved significant efficacy in many cancer immunotherapy,but the effect in the treatment of pancreatic cancer is limited,and the effect of monotherapy is suboptimal.The combined thera-peatic effect of PD-1/PD-L1 and chemotherapy,radiotherapy,and molecular targeted therapy were explored.This article summarises the advancements in PD-1/PD-L1 inhibitor combination therapy in the treatment of pancreatic cancer.
维普
万方数据